Helix BioPharma to Present at 7th Annual BIO Asia Partnering Conference on
January 26


<p>AURORA, Ontario, <chron>Jan. 22</chron> /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP; Pink Sheets:   HXBPF) today announced that Heman Chao, chief scientific officer, will present at The 7th Annual BIO Asia Partnering Conference at <chron>1:00PM</chron> JST on <chron>January 26, 2010</chron> at the Grand Hyatt <location>Tokyo</location> in <location>Tokyo</location> <location>Japan</location>. <person>Dr. Chao</person> will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b.</p>

    About Helix BioPharma Corp.
<p>Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy.  The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b.  Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF".</p>
<p> </p>
<p> </p>
    For further information contact:
    Investor Relations                 Media Relations
    Robert Flamm, Ph.D.                Ian Stone
    Russo Partners LLC                 Russo Partners LLC
    Tel: (212) 845-4226                Tel: (619) 528-2220
     robert.flamm@russopartnersllc.com Email: ian.stone@russopartnersllc.com

<p>This News Release contains certain forward-looking statements and information (collectively, "forward-looking statements") regarding the Company's planned presentation at the BIO Asia Partnering Conference and the Company's product development initiatives. Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the fact that the presentation is subject to change or cancellation without notice; Helix's need for additional future capital, which may not be available in a timely manner or at all; the need for additional research and development, the outcome of which is uncertain; and uncertainty whether L-DOS47 or Topical Interferon Alpha-2b, or any other product development initiatives, will be successfully developed or commercialized. See the Company's latest Form 20-F and other reports filed from time to time on SEDAR at <a href="http://www.sedar.com">www.sedar.com</a>, and on EDGAR at <a href="http://www.sec.gov/edgar.shtml">www.sec.gov/edgar.shtml</a> for a further description of certain of these and other important risks and uncertainties affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements. The Company does not assume any obligation to update any forward-looking statement except as required by law.</p>


For further information: For further information: Investor Relations, Robert Flamm, Ph.D., Russo Partners LLC, +1-212-845-4226, robert.flamm@russopartnersllc.com, or Media Relations, Ian Stone, Russo Partners LLC, +1-619-528-2220, ian.stone@russopartnersllc.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890